An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- 1AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- 2Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- 3Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- 4Outperformed existing clinical scoring systems for early diagnosis.
- 5FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.
Source
EurekAlert
Related News
•EurekAlert
AI and Advanced Microscopy Unveil Cell's Exocytosis Nanomachine
Researchers have discovered the ExHOS nanomachine responsible for constitutive exocytosis using advanced microscopy and AI-enhanced image analysis.
•EurekAlert
Physical Activity Linked to Breast Tissue Biomarkers in Teens
A study links adolescent recreational physical activity to changes in breast tissue composition and stress biomarkers, potentially impacting future breast cancer risk.
•EurekAlert
AI Reveals Key Health System Levers for Cancer Outcomes Globally
AI-based analysis identifies the most impactful policy and resource factors for improving cancer survival across 185 countries.